Personalis, Inc. Common Stock
PSNLPersonalis, Inc. is a biotechnology company specializing in advanced genomic sequencing and data analytics for precision medicine. Founded to improve cancer detection, diagnosis, and treatment, it offers comprehensive genomic profiling solutions that enable clinicians to make more informed decisions. The company's technologies are utilized primarily in oncology, immuno-oncology, and other complex disease areas to facilitate personalized healthcare.
Company News
Personalis reported Q2 2025 financial results with revenue falling 24% year-over-year to $17.2 million, missing estimates. Despite financial challenges, the company saw a 59% increase in clinical test volumes for its NeXT Personal platform, with promising cancer detection research.
AI is transforming healthcare with projected market growth exceeding $110 billion by 2030, enabling advanced diagnostic tools, early disease detection, and more efficient medical research across multiple sectors.
The global gene panel market is projected to reach $11.75 billion by 2031, growing at a CAGR of 19.30% during the forecast period. The market growth is driven by advancements in genomic research, rising prevalence of genetic disorders, and growing awareness of genetic testing.
Tempus AI, a niche AI company, has increased its stake in Personalis, a biotech firm specializing in cancer diagnostics. The move has led to a significant surge in Tempus AI's stock price, outperforming the broader market.
Personalis (NASDAQ:PSNL) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearis...
